AUG 18, 2026 · JOURNAL ARTICLE
Modeling KRAS mutations in KMT2A::MLLT3 acute myeloid leukemia promotes leukemic progression and transcriptional rewiring
Leukemia
A mechanistic preclinical model study with supporting clinical cohort data showing KRAS mutations accelerate KMT2A::MLLT3 AML progression; limited by in vivo mouse model design and observational patient data without controlled comparison.
Reported
Latency acceleration fold-change2.16 ± 0.65-fold
LSC frequency p-value0.0069
LSC frequency fold-increase>20-fold